Taken together, our work shows that microglial NF-κB acts downstream of tau pathology, and directly mediates toxic effects on cognition, highlighting the potential of blocking maladaptive microglial responses instead of removing tau aggregates as a therapeutic strategy to treat tauopathy. This evidence concerns the gene MAPT and tauopathy.